Compare PRTA & RYAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTA | RYAM |
|---|---|---|
| Founded | 2012 | 1926 |
| Country | Ireland | United States |
| Employees | N/A | 2325 |
| Industry | Biotechnology: Pharmaceutical Preparations | Paper |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 539.9M | 741.8M |
| IPO Year | 2013 | 2014 |
| Metric | PRTA | RYAM |
|---|---|---|
| Price | $10.34 | $9.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $19.00 | $14.00 |
| AVG Volume (30 Days) | 470.1K | ★ 752.2K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $814,000.00 | ★ $1,466,397,000.00 |
| Revenue This Year | $1,111.38 | N/A |
| Revenue Next Year | N/A | $8.22 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.32 | $3.35 |
| 52 Week High | $11.69 | $11.85 |
| Indicator | PRTA | RYAM |
|---|---|---|
| Relative Strength Index (RSI) | 62.19 | 48.55 |
| Support Level | $9.69 | $6.91 |
| Resistance Level | $10.37 | $11.62 |
| Average True Range (ATR) | 0.42 | 0.52 |
| MACD | 0.12 | -0.22 |
| Stochastic Oscillator | 84.88 | 39.58 |
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Rayonier Advanced Materials Inc engaged in the production and sale of high-purity cellulose and other cellulose-based materials derived from renewable wood fiber. The company operates through five segments: Cellulose Specialties, which produces purified cellulose used in products such as filters, pharmaceuticals, food additives and electronics; Biomaterials, which produces products including biofuels, lignosulfonates and other bio-based chemicals; Cellulose Commodities, which manufactures absorbent and viscose pulp used in textiles and hygiene products; Paperboard, which produces coated paperboard used for packaging and printing applications; and High-Yield Pulp, which produces pulp used in paperboard, packaging and printing paper products.